Giant Bio IPO: Come, fill up a glass of female Mao __ China Medical Post date May 15, 2022 — 18:30 Post Lock Read More Pathfinder (300005): Record Form of Investor Relations Activities on May 12, 2022 CFi.CN Post date May 13, 2022 — 23:21 Post Lock Read More Weikang Pharmaceutical: At present, there is no cooperation project between the company and Suzhou Wangshan Wangshui Biological Co., Ltd. Post date May 13, 2022 — 16:12 Post Lock Read More Weikang Pharmaceutical: At present, there is no cooperation project between the company and Suzhou Wangshan Wangshui Biological Co., Ltd._ Oriental Fortune Net Post date May 13, 2022 — 16:12 Post Lock Read More Weikang Pharmaceutical: The company and Yingkerui entered the stage of in-depth cooperation. The cooperation projects and categories have also been further extended and expanded_ Oriental Fortune Net Post date May 12, 2022 — 17:51 Post Lock Read More Weikang Pharmaceutical (300878): Holding 2021 Online Performance Briefing-CFi.CN Zhongcai.com Post date May 10, 2022 — 13:56 Post Lock Read More Announcement of Zhongchang Big Data Co., Ltd. on Adding Temporary Proposals for the Second Extraordinary General Meeting of Shareholders in 2022 Post date May 9, 2022 — 03:26 Post Lock Read More *ST Zhongchang (600242): Zhongchang Big Data Co., Ltd. on the addition of a provisional proposal for the second extraordinary general meeting in 2022- CFi.CN Zhongcai Network Post date May 8, 2022 — 18:05 Post Lock Read More Weikang Pharmaceutical: Huangjia Ruangan Granules, the company's product under development, is a 1.1 class of innovative traditional Chinese medicines Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Pathfinder (300005): Record Form of Investor Relations Activities on May 12, 2022 CFi.CN Post date May 13, 2022 — 23:21 Post Lock Read More Weikang Pharmaceutical: At present, there is no cooperation project between the company and Suzhou Wangshan Wangshui Biological Co., Ltd. Post date May 13, 2022 — 16:12 Post Lock Read More Weikang Pharmaceutical: At present, there is no cooperation project between the company and Suzhou Wangshan Wangshui Biological Co., Ltd._ Oriental Fortune Net Post date May 13, 2022 — 16:12 Post Lock Read More Weikang Pharmaceutical: The company and Yingkerui entered the stage of in-depth cooperation. The cooperation projects and categories have also been further extended and expanded_ Oriental Fortune Net Post date May 12, 2022 — 17:51 Post Lock Read More Weikang Pharmaceutical (300878): Holding 2021 Online Performance Briefing-CFi.CN Zhongcai.com Post date May 10, 2022 — 13:56 Post Lock Read More Announcement of Zhongchang Big Data Co., Ltd. on Adding Temporary Proposals for the Second Extraordinary General Meeting of Shareholders in 2022 Post date May 9, 2022 — 03:26 Post Lock Read More *ST Zhongchang (600242): Zhongchang Big Data Co., Ltd. on the addition of a provisional proposal for the second extraordinary general meeting in 2022- CFi.CN Zhongcai Network Post date May 8, 2022 — 18:05 Post Lock Read More Weikang Pharmaceutical: Huangjia Ruangan Granules, the company's product under development, is a 1.1 class of innovative traditional Chinese medicines Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical: At present, there is no cooperation project between the company and Suzhou Wangshan Wangshui Biological Co., Ltd. Post date May 13, 2022 — 16:12 Post Lock Read More Weikang Pharmaceutical: At present, there is no cooperation project between the company and Suzhou Wangshan Wangshui Biological Co., Ltd._ Oriental Fortune Net Post date May 13, 2022 — 16:12 Post Lock Read More Weikang Pharmaceutical: The company and Yingkerui entered the stage of in-depth cooperation. The cooperation projects and categories have also been further extended and expanded_ Oriental Fortune Net Post date May 12, 2022 — 17:51 Post Lock Read More Weikang Pharmaceutical (300878): Holding 2021 Online Performance Briefing-CFi.CN Zhongcai.com Post date May 10, 2022 — 13:56 Post Lock Read More Announcement of Zhongchang Big Data Co., Ltd. on Adding Temporary Proposals for the Second Extraordinary General Meeting of Shareholders in 2022 Post date May 9, 2022 — 03:26 Post Lock Read More *ST Zhongchang (600242): Zhongchang Big Data Co., Ltd. on the addition of a provisional proposal for the second extraordinary general meeting in 2022- CFi.CN Zhongcai Network Post date May 8, 2022 — 18:05 Post Lock Read More Weikang Pharmaceutical: Huangjia Ruangan Granules, the company's product under development, is a 1.1 class of innovative traditional Chinese medicines Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical: At present, there is no cooperation project between the company and Suzhou Wangshan Wangshui Biological Co., Ltd._ Oriental Fortune Net Post date May 13, 2022 — 16:12 Post Lock Read More Weikang Pharmaceutical: The company and Yingkerui entered the stage of in-depth cooperation. The cooperation projects and categories have also been further extended and expanded_ Oriental Fortune Net Post date May 12, 2022 — 17:51 Post Lock Read More Weikang Pharmaceutical (300878): Holding 2021 Online Performance Briefing-CFi.CN Zhongcai.com Post date May 10, 2022 — 13:56 Post Lock Read More Announcement of Zhongchang Big Data Co., Ltd. on Adding Temporary Proposals for the Second Extraordinary General Meeting of Shareholders in 2022 Post date May 9, 2022 — 03:26 Post Lock Read More *ST Zhongchang (600242): Zhongchang Big Data Co., Ltd. on the addition of a provisional proposal for the second extraordinary general meeting in 2022- CFi.CN Zhongcai Network Post date May 8, 2022 — 18:05 Post Lock Read More Weikang Pharmaceutical: Huangjia Ruangan Granules, the company's product under development, is a 1.1 class of innovative traditional Chinese medicines Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical: The company and Yingkerui entered the stage of in-depth cooperation. The cooperation projects and categories have also been further extended and expanded_ Oriental Fortune Net Post date May 12, 2022 — 17:51 Post Lock Read More Weikang Pharmaceutical (300878): Holding 2021 Online Performance Briefing-CFi.CN Zhongcai.com Post date May 10, 2022 — 13:56 Post Lock Read More Announcement of Zhongchang Big Data Co., Ltd. on Adding Temporary Proposals for the Second Extraordinary General Meeting of Shareholders in 2022 Post date May 9, 2022 — 03:26 Post Lock Read More *ST Zhongchang (600242): Zhongchang Big Data Co., Ltd. on the addition of a provisional proposal for the second extraordinary general meeting in 2022- CFi.CN Zhongcai Network Post date May 8, 2022 — 18:05 Post Lock Read More Weikang Pharmaceutical: Huangjia Ruangan Granules, the company's product under development, is a 1.1 class of innovative traditional Chinese medicines Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical (300878): Holding 2021 Online Performance Briefing-CFi.CN Zhongcai.com Post date May 10, 2022 — 13:56 Post Lock Read More Announcement of Zhongchang Big Data Co., Ltd. on Adding Temporary Proposals for the Second Extraordinary General Meeting of Shareholders in 2022 Post date May 9, 2022 — 03:26 Post Lock Read More *ST Zhongchang (600242): Zhongchang Big Data Co., Ltd. on the addition of a provisional proposal for the second extraordinary general meeting in 2022- CFi.CN Zhongcai Network Post date May 8, 2022 — 18:05 Post Lock Read More Weikang Pharmaceutical: Huangjia Ruangan Granules, the company's product under development, is a 1.1 class of innovative traditional Chinese medicines Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Announcement of Zhongchang Big Data Co., Ltd. on Adding Temporary Proposals for the Second Extraordinary General Meeting of Shareholders in 2022 Post date May 9, 2022 — 03:26 Post Lock Read More *ST Zhongchang (600242): Zhongchang Big Data Co., Ltd. on the addition of a provisional proposal for the second extraordinary general meeting in 2022- CFi.CN Zhongcai Network Post date May 8, 2022 — 18:05 Post Lock Read More Weikang Pharmaceutical: Huangjia Ruangan Granules, the company's product under development, is a 1.1 class of innovative traditional Chinese medicines Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
*ST Zhongchang (600242): Zhongchang Big Data Co., Ltd. on the addition of a provisional proposal for the second extraordinary general meeting in 2022- CFi.CN Zhongcai Network Post date May 8, 2022 — 18:05 Post Lock Read More Weikang Pharmaceutical: Huangjia Ruangan Granules, the company's product under development, is a 1.1 class of innovative traditional Chinese medicines Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical: Huangjia Ruangan Granules, the company's product under development, is a 1.1 class of innovative traditional Chinese medicines Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical: The company's product under development, Huangjia Ruangan Granules, is a category 1.1 innovative traditional Chinese medicine drug_Oriental Fortune Network Post date May 7, 2022 — 12:15 Post Lock Read More Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical: The two parties will increase cooperation in the research of new preparations, and further strengthen cooperation in the new technology platforms of Yingke Rui's characteristic new preparations such as aerosol inhalation solutions, nanogels, and in situ gels Post date May 7, 2022 — 11:25 Post Lock Read More Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical: The decline in net profit in the fourth quarter was mainly due to the corresponding progress of some of the company's outsourced R&D projects in the fourth quarter Post date May 7, 2022 — 11:00 Post Lock Read More Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hongya NC (002833): Annual Special Audit Report on Fund Occupation by Related Parties- CFi.CN Zhongcai Network Post date April 30, 2022 — 16:25 Post Lock Read More Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Information Development (300469): Special Report on the Occupation of Non-operating Funds and Other Related Fund Transactions of Shanghai Xinlian Information Development Co., Ltd. in 2021- CFi.CN Zhongcai.com Post date April 30, 2022 — 15:31 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
[Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:55 Post Lock Read More [Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
[Express] Weikang Pharma Announces Annual Report-CFi.CN Post date April 29, 2022 — 13:28 Post Lock Read More Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Are there any medications used to treat hepatitis? Weikang Pharmaceuticals responds Post date April 29, 2022 — 11:49 Post Lock Read More Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical: The company's product, Gansu Capsules, reduces enzymes for chronic active hepatitis and hepatitis B Post date April 29, 2022 — 11:10 Post Lock Read More Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical: The company's research product Huangjia Ruangan Granule is a 1.1 class of innovative traditional Chinese medicine drugs for chronic hepatitis B liver fibrosis Post date April 29, 2022 — 11:08 Post Lock Read More Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weikang Pharmaceutical: The Yinhuang inhalation solution jointly developed by the company and Beijing Yingke Rui is a 2.1 category of improved traditional Chinese medicine. Post date April 29, 2022 — 11:08 Post Lock Read More
Caishen.CoCaishen.Co